Plexus Biomedical, a small device company based in Oakland, TN, has raised $2 million from individual investors, according to an exclusive report by TechJournal South.
The company’s CEO, David Burton, was tight lipped about Plexus’ technology, but research by TechJournal on clinicaltrials.gov uncovered a study by Plexus Biomedical and the University of Tennessee Health Science Center of the HEM-AVERT Perianal Stablizer, a device designed to reduce the occurrence or severity of hemorrhoids during childbirth.
According to clinicaltrials.gov, the HEM-AVERT Perianal Stablizer “is both non-invasive and poses a non-significant risk. It is classified as a manual, general instrument with no specific indications, but has a general indication of stabilizing pressure.”
The study description says there is currently no preventative treatment for the 9-34% of vaginal births that cause hemorrhoids. TechJournal says the study has enrolled 300 patients and is scheduled to start this month.